Halozyme Therapeutics (HALO) Treasury Shares (2010 - 2025)

Halozyme Therapeutics (HALO) has 1 years of Treasury Shares data on file, last reported at $58.9 million in Q3 2020.

• On a quarterly basis, Treasury Shares rose 215.48% year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $1.5 million, a 215.48% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 215.48% from the prior year.
• Treasury Shares for Q4 2025 stood at $1.5 million, up from $482403.0 in the prior quarter.
• Over the last five years, Treasury Shares for HALO reached as high as $1.5 million in Q4 2025 and fell as low as $482403.0 in Q4 2024.
• Historically, Treasury Shares has averaged $1.0 million across 5 years, with a median of $1.0 million in 2022.
• Across the five-year window, Treasury Shares tumbled 57.66% in 2024 and surged 215.48% in 2025, its largest moves.
• Year by year, Treasury Shares stood at $858742.0 in 2021, then grew by 21.04% to $1.0 million in 2022, then grew by 9.62% to $1.1 million in 2023, then tumbled by 57.66% to $482403.0 in 2024, then jumped by 215.48% to $1.5 million in 2025.
• Per Business Quant data, the three most recent Treasury Shares figures were $58.9 million in Q3 2020, $2.0 million in Q2 2020, and $51.6 million in Q1 2020.